| P562 | Delayed immune-related events after discontinuation of immunotherapy – DIRE syndrome? | Marcus A. Couey, MD, DDS; Bryan R. Bell, MD, DDS, FACS; Ashish Patel, MD; Marka R. Crittenden, MD, PhD; Brendan D. Curti, MD; Rom Leidner, MD; | Autoimmunity; Checkpoint blockade; Costimulation; Immune toxicity; Inflammation; Surgery |
| P563 | Characterizing immune-mediated adverse events of anti-PD-1 and anti-CTLA-4 monotherapies and combinations using a quantitative model based meta-analysis | Boris Shulgin, PhD; Yuri Kosinsky, PhD; Andrey Omelchenko, PhD; Lulu Chu, PhD; Ganesh Mugundu, PhD; Garrett J. DeYulia, Jr., PhD; Rodrigo Pimentel, MD; Kirill Peskov, PhD; Gabriel Helmlinger, PhD; | Checkpoint blockade; Clinical trial; Immune toxicity; Solid tumors |
| P564 | Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis | Daniel H. Johnson, MD; Cara Haymaker, PhD; Khalida Wani, PhD; Wai Chin Foo, MD; Salah Eddine Bentebibel; Yinghong Wang, MD, PhD; Jonathan L. Curry, MD; Adi Diab, MD; Jennifer A. Wargo, MD, MMSc; Alexandre Reuben; Elizabeth Burton; | Autoimmunity; Checkpoint blockade; Cytokine; Gene expression; Immune toxicity; Inflammation; Tumor microenvironment |
| P565 | Characterization of lymphoid cells in synovial fluid from cancer patients with immunotherapy-associated arthritis | Sang Kim, MD, PhD; Roza Nurieva, PhD; Jean H. Tayar, MD; Huifang Lu, MD, PhD; Jennifer Wang, MD; Don Gibbons, MD; Guillermo Garcia-Manero, MD; Maria Suarez-Almazor, MD, PhD; Patrick Hwu, MD; Adi Diab, MD; | Autoimmunity; Checkpoint blockade; Inflammation; T cell |
| P566 | Hypoalbuminemia as a predictor factor for immune related adverse events (irAEs) in advanced melanoma patients treated with immune checkpoint inhibitors (ICIs) | Steven Blum, MD; Jeffrey Ishizuka, M.D.,D.Phil; Taha M. Qazi, MD; Rawad Elias, MD; Kruti B. Vora, BA; Alex B. Ruan; Anita Giobbie-Hurder, MS; Shilpa Grover, MD, MPH; Rizwan Haq, MD, PhD; Meredith Davis; Maria E. Gargano, PA-C; Elizabeth Buchbinder, MD; Patrick A. Ott, MD, PhD; F. Stephen Hodi, Jr., MD; E E. Rahma, MD; | Checkpoint blockade; Immune toxicity |
| P567 | A meta-analysis of immune checkpoint inhibitors tumor type and dose-toxicity correlation | E E. Rahma, MD; Joshua E. Reuss, MD; Ghazaleh GR. Shoja E Razavi, MD; Rawad Elias, MD; Anita Giobbie-Hurder, MS; Samir N. Khleif, MD; | Checkpoint blockade; Immune toxicity |
| P568 | Pembrolizumab induced multiple immune related adverse events including myasthenia gravis, hepatitis and thyroiditis in a patient with thymoma | Kyunghoon Rhee, MD; Taeyeong ko, MD; Sangmin Chang, MD; Ji Hyun Rhee, MD; Lee Chun Park, MD; Young Kwang Chae, MD; | Autoimmunity; Checkpoint blockade; Immune toxicity |
